Adeptus Biotechnologies Corp. (ADPT) PT Raised to $21 at Guggenheim
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ADPT Hot Sheet
Price: $26.71 --0%
Rating Summary:
13 Buy, 3 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 24 | New: 2
Rating Summary:
13 Buy, 3 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 24 | New: 2
Join SI Premium – FREE
Guggenheim analyst Subbu Nambi raised the price target on Adeptus Biotechnologies Corp. (NASDAQ: ADPT) to $21.00 (from $20.00) while maintaining a Buy rating.
You May Also Be Interested In
- Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results
- Capricorn Metals Ltd (CMM:AU) PT Lowered to AUD17.50 at Goldman Sachs
- Medline Inc (MDLN) PT Lowered to $44 at Evercore ISI
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
